Sumitomo Pharma Co.Ltd. 4506
TSE · Japan · Health Technology
¥1,635.00+8.50 (+0.52%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Asian stock markets turned in a choppy Thursday, as traders weighed easing petroleum prices but also
By Karen Roman Slate Medicines Inc. said it appointed Kenneth Koblan, PhD, as its new Chief Scientific Officer, having previously served as Head of Research and Development at Vesalius Therapeutics, and at Sumitomo Pharma America as Chief Scientific Officer and Head of Development Operations. Dr. Koblan is a biopharmaceutical R&D leader with more than 30 years […] The post Slate Medicines Names Kenneth Koblan as Chief Scientific Officer appeared first on ExecEdge.
Nuvisertib targets unmet needs in relapsed/refractory myelofibrosis with differentiated, potentially disease-modifying activity. Combination therapy, expansion into other cancers and expedited regulatory pathways offer additional opportunities.Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "Nuvisertib Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. Nuvisertib (TP-3654) is an investigational, orally administered, highly selective PIM1 kinase i
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.